两家投资公司购买了价值近130万美元的癌症治疗公司Iovance生物治疗药物。 Two investment firms buy nearly $1.3 million worth of Iovance Biotherapeutics, a cancer treatment company.

黑文资本集团和肯农代尔资本管理两家投资公司购买了Iovance生物治疗公司的股份,该公司是一家生物技术公司,为癌症治疗开发细胞疗法。 Two investment firms, Haven Capital Group and Kennondale Capital Management, have purchased shares of Iovance Biotherapeutics, a biotech company that develops cell therapies for cancer treatments. Haven Capital购买了124 449美元的股票,价值921 000美元,Kenondale购买了52 769美元的股票,价值390 000美元。 Haven Capital bought 124,449 shares worth $921,000, while Kennondale acquired 52,769 shares valued at $390,000. Iovance 的股票周二开盘价为 3.74 美元，市值为 12.3 亿美元。 Iovance's stock opened at $3.74 on Tuesday, with a market cap of $1.23 billion. 该公司的治疗方法包括分别治疗黑瘤和肾细胞癌的Amtagvi和Proleukin疗法。 The company's therapies include Amtagvi and Proleukin for treating melanoma and renal cell carcinoma, respectively.